ERAS
Price
$2.00
Change
+$0.04 (+2.03%)
Updated
May 20, 9:45 AM EST
80 days until earnings call
GLUE
Price
$5.01
Change
-$0.19 (-3.65%)
Updated
May 20, 12:25 PM EST
80 days until earnings call
Ad is loading...

ERAS vs GLUE

Header iconERAS vs GLUE Comparison
Open Charts ERAS vs GLUEBanner chart's image
Erasca
Price$2.00
Change+$0.04 (+2.03%)
Volume$4.31K
CapitalizationN/A
Monte Rosa Therapeutics
Price$5.01
Change-$0.19 (-3.65%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
ERAS vs GLUE Comparison Chart

Loading...

ERASDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GLUEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ERAS vs. GLUE commentary
May 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and GLUE is a Hold.

COMPARISON
Comparison
May 20, 2024
Stock price -- (ERAS: $1.97 vs. GLUE: $5.20)
Brand notoriety: ERAS and GLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 1336% vs. GLUE: 90%
Market capitalization -- ERAS: $341.52M vs. GLUE: $262.66M
ERAS [@Biotechnology] is valued at $341.52M. GLUE’s [@Biotechnology] market capitalization is $262.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $586.12B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileGLUE’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • GLUE’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than GLUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while GLUE’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 7 bearish.
  • GLUE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +6.49% price change this week, while GLUE (@Biotechnology) price change was +7.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +5.50%, and the average quarterly price growth was +63.17%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 08, 2024.

GLUE is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ERAS with price predictions.
OPEN
A.I.dvisor published
a Summary for GLUE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ERAS($342M) has a higher market cap than GLUE($263M). ERAS YTD gains are higher at: -7.512 vs. GLUE (-7.965).
ERASGLUEERAS / GLUE
Capitalization342M263M130%
EBITDAN/AN/A-
Gain YTD-7.512-7.96594%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
ERASGLUE
RSI
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
89%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 19 days ago
78%
Bullish Trend 6 days ago
87%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
88%
Aroon
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
85%
View a ticker or compare two or three
Ad is loading...
ERASDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GLUEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AGRFX116.230.23
+0.20%
AB Growth A
FDSSX75.680.12
+0.16%
Fidelity Stock Selec All Cp
WHGOX11.770.01
+0.09%
Westwood Income Opportunity Ultra
ERSGX13.910.01
+0.07%
Eaton Vance Small-Cap R
TRXIX11.58N/A
N/A
Catalyst/MAP Global Balanced I

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+6.49%
XNCR - ERAS
43%
Loosely correlated
+2.54%
NTLA - ERAS
43%
Loosely correlated
+0.19%
GLUE - ERAS
41%
Loosely correlated
-0.38%
BEAM - ERAS
40%
Loosely correlated
+3.49%
TNYA - ERAS
38%
Loosely correlated
+9.65%
More